A
Agilent Technologies, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 152.88K | $24.44M | n/a | n/a |
| Q2 2026 | 166 | +3 | 195.92M | $26.03B | +9 | −5 |
| Q1 2026 | 165 | -3 | 181.10M | $20.68B | +3 | −7 |
| Q4 2025 | 167 | +1 | 200.20M | $27.23B | +3 | −1 |
| Q3 2025 | 22 | +2 | 109.95M | $14.10B | +3 | −2 |
| Q2 2025 | 18 | -1 | 102.37M | $12.08B | n/a | −1 |
| Q1 2025 | 16 | -1 | 41.13M | $4.81B | n/a | −1 |
| Q4 2024 | 17 | +1 | 41.24M | $5.54B | +2 | −1 |
| Q3 2024 | 15 | -1 | 26.67M | $3.96B | +1 | −2 |
| Q2 2024 | 16 | n/a | 29.82M | $3.86B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 113.00K | +8.7% | $17.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 35.11K | +68.0% | $6.05M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 4.76K | -4.5% | $793,964 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,065 holders, 251.21M shares, $26.86B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 634 sh · $95,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology